Immunovant, Inc.: financial statements

IMVTNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$31.77

November 20, 2026Market cap $6.5B

What Ploutos Investor adds for Immunovant

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from FY2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2024–FY2026 fiscal years

Click a line to see it on the chart.

Operating income

LineFY2024FY2025FY2026Average a year
Operating income -$259M-$413M-$505M
Net income -$259M-$414M-$506M
Earnings per share -$1.88-$2.73-$2.77
Earnings per share, basic -$1.88-$2.73-$2.77

Financial statements

IMVT's revenue, profits and cash flows from FY2019 to FY2023, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

In some years the company reports no operating income, so we show pre-tax income.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

-0.0% Effective tax rate

From the statutory to the effective tax rate, FY2026

Mar 31, 2026

Statutory rate

21.0%

Effective rate

-0.0%

-21.0 pts

The company paid -0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance · Switzerland

+15.9 pts

Cross-border effects

+12.8 pts

Tax credits

+2.9 pts

Other deductions

+1.4 pts

Non-deductible expenses

+0.2 pts

Intra-group transfers

-27.4 pts

Foreign rate differential

-15.0 pts

Change in valuation allowance · United States

-10.0 pts

Executive pay deduction limit

-1.7 pts

Effective rate

-0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.

Effective tax rate by year

The tax rate IMVT paid on its profit, from FY2019 to FY2023, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Taxes: deferred and paid

The deferred part was 0.0% of the tax charge in the year to Mar 31, 2026. The rows show the last 3 years.

Cash taxes paid were 1,109.8% of the current tax charge in the year to Mar 31, 2026.

Deferred share, year to Mar 31, 2026$0 of $215.0K
0.0%
Deferred share, year to Mar 31, 2025$0 of $891.0K
0.0%
Deferred share, year to Mar 31, 2024$0 of $567.0K
0.0%
$2.4M paid, $215.0K current
1,109.8%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs two fiscal years in a row.

Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Immunovant's filings show?

These are Immunovant's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about IMVT's financials

Didn't find what you were looking for?

Ask us
How much debt does IMVT have?

On March 31, 2026 Immunovant had total assets of $957M, debt of – and shareholders' equity of $853M.

How much free cash flow does IMVT have?

In fiscal FY2026 Immunovant had cash from operations of -$407M and spent $8.0K on capital expenditure, leaving -$407M of free cash flow.

Where are the figures from?

From Immunovant, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.